Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Shares Outstanding (Diluted Average) (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) changed 0.37% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, changed 0.37% year-over-year, with the annual reading at $7.3 million for FY2025, 0.37% changed from the prior year.
  • Shares Outstanding (Diluted Average) hit $7.3 million in Q4 2025 for Kezar Life Sciences, roughly flat from $7.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $72.5 million in Q2 2023 to a low of $6.7 million in Q4 2022.
  • Historically, Shares Outstanding (Diluted Average) has averaged $30.0 million across 5 years, with a median of $7.3 million in 2025.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 27.2% in 2022 and later crashed 89.95% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $52.8 million in 2021, then tumbled by 87.23% to $6.7 million in 2022, then rose by 7.7% to $7.3 million in 2023, then grew by 0.48% to $7.3 million in 2024, then rose by 0.37% to $7.3 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for KZR at $7.3 million in Q4 2025, $7.3 million in Q3 2025, and $7.3 million in Q2 2025.